DEFA14A: INVO Fertility Updates Meeting, Implements Reverse Stock Split, and Clarifies Voting Standard

INVO Fertility, Inc. filed a supplement to its 2025 Annual Meeting proxy statement, confirming updated meeting details, announcing a 1-for-3 reverse stock split effective July 21, 2025, and correcting the voting standard for a proposal to increase authorized common stock.

Summary

• The 2025 Annual Meeting of Shareholders, initially held on June 25, 2025, and adjourned to July 9, 2025, has been re-adjourned to Wednesday, July 23, 2025, at 12:00 pm Eastern Time, to be held virtually.
• A 1-for-3 reverse stock split will be effective at 12:01 a.m. Eastern Time on July 21, 2025, with post-split trading commencing on The Nasdaq Capital Market under the same trading symbol, IVF, on the same day.
• Immediately after the reverse stock split, the company will have approximately 928,272 shares of common stock issued and outstanding, and 1,388,888 authorized shares.
• The increase in authorized shares is necessary for the conversion of Series C-2 Preferred Stock, Amended and Restated Debenture, and Inducement Warrants, reservation of 400,000 shares for the 2019 Stock Incentive Plan, and to enable future equity capital raises for acquiring in vitro fertilization clinics to reach cash flow breakeven.
• Executive compensation details for 2024 and 2023 were updated, including salaries for Steven Shum ($260,000 in 2024), Andrea Goren ($215,000 in 2024), Dr. Daniel Teper ($137,548 from Oct 11-Dec 31, 2024), and Michael Campbell ($192,500 in 2024).
• Outstanding equity awards as of December 31, 2024, adjusted for the reverse stock split, include options for Steven Shum (5,087 exercisable, 582 unexercisable), Andrea Goren (5,035 exercisable, 486 unexercisable), and Michael Campbell (6,108 exercisable, 470 unexercisable).
• The voting standard for Proposal 3 (Common Stock Increase Proposal) has been updated to require an affirmative vote of stockholders representing a majority of the votes cast on the matter, following Nevada Revised Statutes amendments. Broker non-votes and abstentions will have no effect on the voting.

Sentiment

Score: 4

Explanation: The document presents a mix of procedural updates and strategic intentions. The reverse stock split is often viewed negatively as it can indicate a low share price or delisting risk, but it's also a necessary step for Nasdaq compliance. The stated purpose of raising capital for acquisitions to reach cash flow breakeven is a positive strategic goal, but the need for capital implies current financial challenges and potential dilution. The overall sentiment is slightly negative due to the implications of the reverse split, partially offset by the growth strategy.

Positives

• The proposed increase in authorized shares aims to enable the company to raise equity capital for acquiring in vitro fertilization clinics, which is a strategic move to reach cash flow breakeven.

Negatives

• The 1-for-3 reverse stock split, while potentially necessary for Nasdaq listing compliance, often signals a low share price and can be perceived negatively by investors.
• The need to raise equity capital implies current financial needs and could lead to shareholder dilution.

Risks

• Forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond the company's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements.
• Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in the company's filings at www.sec.gov.

Future Outlook

The company intends to raise equity capital to pursue its business and operating objectives, primarily the acquisition of in vitro fertilization clinics, with the goal of reaching cash flow breakeven as soon as possible.

Management Comments

• The Company's CEO, acting as chairman of the Annual Meeting, adjourned the Annual Meeting to Wednesday, July 23, 2025, at 12:00 pm Eastern Time.
• Mr. Shum voluntarily agreed to temporarily reduce the annual base salary under his employment agreement from $260,000 to $105,000 until further notice, which reduction took effect on August 16, 2023.
• Mr. Goren voluntarily agreed to temporarily reduce the annual base salary under his employment agreement from $215,000 to $105,000 until further notice, which reduction took effect on August 16, 2023.
• Effective November 15, 2024, Mr. Campbell retired from the Company, and Mr. Campbell and the Company mutually agreed to terminate his employment agreement.

Industry Context

The company operates in the fertility sector, specifically mentioning the acquisition of in vitro fertilization (IVF) clinics, indicating a strategy of growth through consolidation within this specialized healthcare industry.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders are directly impacted by the 1-for-3 reverse stock split, which reduces the number of shares held but increases the per-share price proportionally. They are also subject to potential dilution from future equity capital raises. Their voting rights for Proposal 3 are clarified.
• Management and employees' executive compensation details are updated, and severance terms for key executives are outlined. Michael Campbell's retirement and Dr. Daniel Teper's appointment are noted.
• Creditors and investors may view the company's intention to raise equity capital and acquire IVF clinics to reach cash flow breakeven as a strategic direction that could impact future financial stability and debt servicing capacity.

Next Steps

• The re-adjourned 2025 Annual Meeting of Shareholders will be held virtually on July 23, 2025, at 12:00 pm Eastern Time to vote on Proposal 3.
• The 1-for-3 reverse stock split will become effective at 12:01 a.m. Eastern Time on July 21, 2025.
• The company plans to raise equity capital for additional acquisitions of in vitro fertilization clinics.

Key Dates

Keywords

INVO Fertility, SEC filing, DEFA14A, proxy statement, reverse stock split, common stock, authorized shares, shareholder meeting, corporate governance, executive compensation, equity awards, capital raise, IVF clinics, Nasdaq, voting standard